8-KLeadership ChangesExhibits & Filings

Guardant Health, Inc. 8-K Report, Executive Changes (Oct 24, 2024)

Filed October 24, 2024For Securities:GH

Summary

Guardant Health, Inc. (GH) has announced a significant update to its Board of Directors composition, effective October 21, 2024. The Board has been expanded to ten directors with the appointment of Roberto Mignone as a Class I director. Mr. Mignone brings extensive experience from the investment management sector, notably as the Founder and Managing Partner of Bridger Management LLC, a firm with a strong focus on the healthcare sector. His appointment is expected to enhance the Board's strategic oversight, particularly given his background in long-term equity strategies and deep research expertise in healthcare. In connection with his appointment, Mr. Mignone has also been appointed to the Board's audit committee, further reinforcing the company's governance structure. He will receive standard compensation for non-employee directors, including initial stock option and restricted stock unit awards valued at $362,500, with a vesting schedule tied to his continued service. The company has also entered into its standard indemnification agreement with Mr. Mignone. This move signals a potential strengthening of the Board's financial and strategic acumen, particularly relevant for a company operating in the rapidly evolving diagnostics and precision oncology market.

Key Highlights

  • 1Guardant Health expanded its Board of Directors to ten members.
  • 2Roberto Mignone was appointed as a Class I director, effective October 21, 2024.
  • 3Mr. Mignone is the Founder and Managing Partner of Bridger Management LLC, an investment firm with a healthcare focus.
  • 4He has been appointed to the Board's audit committee.
  • 5Mr. Mignone will receive standard non-employee director compensation, including stock options and RSUs valued at $362,500.
  • 6The company has entered into its standard indemnification agreement with Mr. Mignone.
  • 7There are no undisclosed arrangements or reportable transactions involving Mr. Mignone.

Frequently Asked Questions

Roberto Mignone is the Founder and Managing Partner of Bridger Management LLC, an investment management firm founded in 2000. Bridger Management focuses on long-term equity strategies, with significant expertise in the healthcare sector. Previously, he co-founded and was a partner at Blue Ridge Capital LLC. He also holds significant roles at NYU Langone Medical Center and has degrees from Harvard College and Harvard Business School.

Mr. Mignone's appointment expands the Board's size and brings valuable experience from the investment management industry, particularly within healthcare. His position on the audit committee suggests an increased focus on financial oversight and governance, which is crucial for investor confidence and strategic decision-making.

Mr. Mignone will receive the standard compensation for non-employee directors. This includes an initial stock option award and a restricted stock unit award, each valued at $362,500. These awards will vest over a period of four years, with one-fourth vesting on the first anniversary of his appointment and the remainder vesting monthly over the subsequent three years, contingent on continued service.

According to the filing, there are no arrangements or understandings between Mr. Mignone and any other person regarding his selection as a director. Furthermore, there are no transactions in which Mr. Mignone has an interest that would be reportable under Item 404(a) of Regulation S-K, indicating no apparent conflicts of interest at this time.